Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202683 | 0.84 | KDM4E (0.38) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL9207374 | 0.83 | TARBP2 (0.43) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL2200601 | 0.83 | FBP1 (0.35) | FBP1TARBP2ALDH1A1MAPTNPC1 | |
| SCHEMBL9203907 | 0.82 | TARBP2 (0.42) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL2616840 | 0.80 | TARBP2 (0.58) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL7940493 | 0.77 | TARBP2 (0.48) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL361590 | 0.77 | ALDH1A1 (0.50) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL19207030 | 0.77 | TARBP2 (0.49) | FBP1TARBP2ALDH1A1CYP1A2MAPT | |
| SCHEMBL24424625 | 0.77 | FBP1 (0.72) | FBP1TARBP2ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3820081 | 0.77 | TARBP2 (0.46) | FBP1TARBP2ALDH1A1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | FBP1 270/4885TARBP2 1281/4885ALDH1A1 1844/4885 |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | FBP1 2746/4885TARBP2 4567/4885ALDH1A1 1403/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | FBP1 2746/4885TARBP2 4567/4885ALDH1A1 1403/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | FBP1 2746/4885TARBP2 4567/4885ALDH1A1 1403/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | FBP1 2878/4885TARBP2 4584/4885ALDH1A1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.